NCT00542724已完成3 期
An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject™ and Regular Human Insulin in Patients With Type 1 Diabetes Mellitus
Biodel0 个研究点目标入组 462 人开始时间: 2006年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 462
- 主要终点
- Change in HbA1c
研究概览
简要总结
The purpose of this study is to demonstrate equivalent blood glucose control in patients with type 1 diabetes mellitus with insulin VIAject™ and regular human insulin as prandial insulin and to demonstrate an equivalent safety profile for VIAject™ in comparison to regular human insulin.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients with type 1 diabetes must present with the following:
- •Established diagnosis of type 1 diabetes for more than 1 year.
- •HbA1c values of not more than 10.5%.
- •Three months on a stable insulin regimen that meets the current standard of care and that includes at least two daily insulin injections.
- •Age: 18 to 70 years.
- •Body Mass Index: 18 - 38 Kg/m2.
排除标准
- •Patients presenting with any of the following will not be included in the study:
- •Type 2 diabetes mellitus as determined by the investigator.
- •History of frequent severe hypoglycemia within the prior six months.
- •C-peptide > 1.0 ng/ml unless there is a documented history of ketoacidosis or a documented history of a positive anti GAD test.
- •History of known hypersensitivity to any of the components in the study medication.
- •History of severe or multiple allergies.
- •Treatment with investigational diabetes drug in the last 3 months or treatment with any other investigational drug in the last 30 days before study entry.
- •Current short-term treatment with systemic oral, injected, or inhaled corticosteroids. (inhaled corticosteroids may be allowed when the treatment is long-term).
- •Progressive disease likely to prove fatal.
- •History of malignancy within the past 5 years except for basal cell epithelioma.
- •Known significant hepatic disease or serum AST or ALT values ≥ 3 X upper limit of normal or bilirubin levels ≥ 1.5 X upper limit of normal.
- •Severe complications of diabetes mellitus including a history or finding of Stage III or IV diabetic retinopathy, proteinuria > 2+ by urine dipstick, serum creatinine of >1.8 mg/dl for males or >1.5 mg/dl for females, history of renal transplant, severe peripheral vascular disease which has resulted in an amputation, chronic foot ulcers claudication or absent pedal pulses.
- •Known history of autonomic neuropathy.
- •History of moderate to severe ketoacidosis within the 3 months preceding screening for the study.
- •Current drug or alcohol abuse, or a history which in the opinion of the Investigator will impair patient safety or protocol compliance.
- •Current significant cardiovascular, respiratory, gastrointestinal, hepatic, renal, neurological, psychiatric and/or hematological disease as evaluated by the Investigator.
- •Blood donation within the last 30 days.
- •A woman who is breast feeding.
- •Pregnant women or women intending to become pregnant during the study.
- •A sexually active woman of childbearing age not actively and consistently practicing birth control by using a medically accepted device or therapy.
- •Abnormal ECG, safety lab or physical examination results which, in the opinion of the investigator, render the participation of the patient in the study to be inappropriate or unsafe.
- •A history of lack of compliance with medical instructions, recent drug or alcohol abuse, or other reasons which, in the opinion of the investigator, render the participation of the patient in the study to be inappropriate or unsafe.
- •Current significant diseases of the adrenal gland, pituitary gland or thyroid at the discretion of the investigator.
- •Glomerular Filtration Rate < 40 ml/min.
研究组 & 干预措施
A
Experimental
VIAject™
干预措施: VIAject™ (Drug)
B
Active Comparator
Regular Human Insulin
干预措施: Regular Human Insulin (Drug)
结局指标
主要结局
Change in HbA1c
时间窗: 6 months
To evaluate the mean changes in hemoglobin A1c (HbA1c) from baseline to the end of the study in subjects with type 1 diabetes after treatment for 6 months with Viaject in comparison to the mean changes in HbA1c from baseline to end of study in subjects treated with regular human insulin (RHI).
次要结局
未报告次要终点
研究者
相似试验
已完成
3 期
An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject™ and Regular Human Insulin in Patients With Type 2 Diabetes MellitusType 2 Diabetes MellitusNCT00542633Biodel472
已完成
不适用
SWITCH - Sensing With Insulin Pump Therapy to Control HbA1cDiabetes Mellitus, Type 1NCT00598663Medtronic Diabetes153
Unknown
不适用
The Mobile Diabetes Mgmt. Study With Type 2 DiabetesType 2 DiabetesNCT02451631Healthconnect184
已完成
不适用
Assessing the Effectiveness of Diabetes Interactive Diary (DID) in Diabetes ManagementType 1 Diabetes MellitusNCT00482443The Royal Bournemouth Hospital20
已完成
不适用
Assessment of a New Closed-loop Algorithm in Type 1 Diabetes (Saddle Point Model Predictive Control : SP-MPC) (PPA)Type 1 DiabetesNCT02061488Rennes University Hospital10